Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
68.14
+0.77 (1.14%)
At close: Mar 9, 2026, 4:00 PM EDT
68.25
+0.11 (0.16%)
After-hours: Mar 9, 2026, 7:48 PM EDT
Halozyme Therapeutics Employees
Halozyme Therapeutics had 423 employees as of December 31, 2025. The number of employees increased by 73 or 20.86% compared to the previous year.
Employees
423
Change (1Y)
73
Growth (1Y)
20.86%
Revenue / Employee
$3,301,681
Profits / Employee
$749,147
Market Cap
8.04B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 423 | 73 | 20.86% |
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | 132 | -149 | -53.02% |
| Dec 31, 2018 | 281 | 26 | 10.20% |
| Dec 31, 2017 | 255 | -4 | -1.54% |
| Dec 31, 2016 | 259 | 43 | 19.91% |
| Dec 31, 2015 | 216 | 63 | 41.18% |
| Dec 31, 2014 | 153 | -17 | -10.00% |
| Dec 31, 2013 | 170 | 18 | 11.84% |
| Dec 31, 2012 | 152 | 17 | 12.59% |
| Dec 31, 2011 | 135 | 33 | 32.35% |
| Dec 31, 2010 | 102 | -38 | -27.14% |
| Dec 31, 2009 | 140 | 10 | 7.69% |
| Dec 31, 2008 | 130 | 38 | 41.30% |
| Dec 31, 2007 | 92 | 52 | 130.00% |
| Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 925 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Krystal Biotech | 295 |
| Nuvalent | 228 |
HALO News
- 3 days ago - U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma - PRNewsWire
- 5 days ago - Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 12 days ago - Halozyme to Participate in Upcoming Investor Conferences - PRNewsWire
- 19 days ago - Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge - Seeking Alpha
- 19 days ago - Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE - PRNewsWire
- 27 days ago - Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - PRNewsWire
- 4 weeks ago - Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth - Seeking Alpha